Reply to Jain et al

Affiliations

¹ Division of Pharmacy, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston.
² Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston.

Comment

Farnaz Foolad et al. Clin Infect Dis. 2019.

. 2019 Nov 27;69(12):2235-2236.

doi: 10.1093/cid/ciz379.

¹ Division of Pharmacy, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston.
² Department of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston.

No abstract available

Comment on

Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
Foolad F, Aitken SL, Shigle TL, Prayag A, Ghantoji S, Ariza-Heredia E, Chemaly RF. Foolad F, et al. Clin Infect Dis. 2019 May 2;68(10):1641-1649. doi: 10.1093/cid/ciy760. Clin Infect Dis. 2019. PMID: 30202920 Free PMC article.
Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe?
Jain SR, Phoompoung P, Husain S. Jain SR, et al. Clin Infect Dis. 2019 Nov 27;69(12):2234-2235. doi: 10.1093/cid/ciz376. Clin Infect Dis. 2019. PMID: 31075174 Free PMC article. No abstract available.